Shares of DSKX continues to rally from last week after they held a conference call to discuss the recently announced agreement to acquire Radiancy, Inc., a leading developer of consumer medical devices and the Neova® dermatological products.
It appears investors are beginning to notice the financial value this new deal brings and the future outlook of the company,...
Synthetic Biology is an emerging area of biotech thats clearly outperforming the broader biotech sector this year. (NASDAQ:IBB +31% YTD) Stocks surging in this space include ZIOPHARM Oncology (ZIOP), Intrexon (XON), and Synthetic Biologics (SYN). On average the three are up 167% YTD while the Nasdaq's biotech index (IBB) is up 31%. Definitely worth keeping an eye on.